Data completeness
0/8 — Limited
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Diasone Sodium (sulfoxone sodium) is an oral delayed-release tablet in pre-launch development by AbbVie. The specific indication and mechanism of action are not yet publicly disclosed, reflecting its early-stage regulatory status.
Pre-Launch
Pre-launch status indicates imminent commercial team scaling; early-career opportunities exist in launch planning, market access, and field build.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on Diasone Sodium offers ground-floor opportunity to shape a new product launch within AbbVie's portfolio. Pre-launch roles are typically cross-functional and high-visibility, suited for professionals seeking launch experience and rapid skill development.
Regulatory Affairs SpecialistManufacturing Coordinator
Worked on DIASONE SODIUM at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.